1. India Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Zota Health Care Limited

Zota Health Care Limited

ZOTA.NS
Zota Health Care LimitedIN flagNational Stock Exchange of India
1,225.60
INR
+82.30
- -
37.18BMarket Cap
Zota Health Care Limited
ZOTA.NS
(National Stock Exchange of India)

Recent

price

1,225.60

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
18.97
- -
21.84
24.92
28.08
32.19
35.6
32.34
34.86
38.73
43.48
52.72
55.63
70.38
107.43
- -
122.33
Revenue per Share
0.99
- -
1.27
1.56
2.12
2.54
2.76
3.02
2.26
1.12
-0.09
3.58
-2.29
-5.59
-20.68
- -
-20.85
Basic EPS, GAAP
0.66
- -
1.04
0.94
1.77
1.58
0.71
-2.39
-2.59
-0.25
-1.68
4.05
-5.77
-8.85
-35.18
- -
- -
Free Cash Flow per Basic Share
0.5
- -
0.6
0.6
0.71
0.71
0.71
1.46
2.14
1
1
1.01
1.5
1.01
1
- -
- -
Dividend per Share
- -
- -
7.53
8.39
10.98
11.65
14.28
15.55
13.17
15.99
14.96
17.63
28.18
9.4
3.46
- -
- -
Book Value per Share
- -
- -
6.9
7.76
9
11.1
12.53
28.03
26.77
25.02
24.36
33.82
30.23
33.5
81.49
- -
- -
Tangible Book Value per Share
20
- -
20
20
20
20
20
24
25
25
25
25
25
26
27
- -
28
Basic Weighted Avg Shares
381
- -
439
501
565
647
716
779
856
951
1,068
1,312
1,400
1,805
2,930
5,387
3,403
Sales/Revenue/Turnover
9.02
- -
10.36
10.7
12.35
12.94
12.56
12.8
7.67
2.61
-2.01
8.54
-2.73
-6.99
-16.7
-11.87
-14.8
Operating Margin (%)
14
- -
14
12
15
12
11
9
14
21
32
37
120
202
432
825
498
Depreciation Expense
20
- -
26
31
43
51
55
73
55
27
-2
89
-58
-143
-564
-739
-580
Net Income, GAAP
33.03
- -
32.6
33.37
32.59
33.85
33.73
35.92
29.37
29
- -
28.39
- -
- -
- -
- -
- -
Effective Tax Rate (%)
5.2
- -
5.82
6.25
7.55
7.89
7.74
9.34
6.48
2.88
-0.2
6.79
-4.12
-7.95
-19.25
-13.73
-17.04
Profit Margin (%)
- -
60
80
100
121
173
207
344
426
403
430
409
437
379
835
2,199
- -
Working Capital
- -
30
30
32
20
22
25
- -
- -
- -
- -
125
363
632
1,075
1,899
- -
LT Debt
- -
127
139
156
181
232
270
698
689
688
663
896
804
900
2,272
6,962
- -
Total Equity
- -
- -
17.12
18.79
21.88
22.84
21.09
12.66
6.69
2.56
- -
9.39
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
16.06
17.63
19.43
20.97
20.46
20.89
15.94
7.68
- -
19.04
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
17.63
19.55
21.87
22.45
21.25
21.98
15.9
7.65
-0.55
22.1
-10.06
-30.2
-336.31
-335.48
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
ST Debt
- -
321
- -
LT Borrowings
- -
50
- -
LT Finance Leases
- -
1,026
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
29
- -
Market Capitalization
21,486
21,879
27,105

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'25
Jun'26
Total Current Assets
- -
1,842
- -
Cash, Cash Equivalents & STI
- -
36
- -
Accounts Receivable, Net
- -
405
- -
Inventories
- -
1,057
- -
Total Current Liabilities
- -
1,006
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
321
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
56.58%
79.15%
206.47%
Free Cash Flow
-17.5%
-20.72%
105.7%
Net Income, GAAP
-419.84%
-811.23%
31.1%
Sales/Revenue/Turnover
25.74%
40.93%
83.86%
Total Cash Common Dividend
- -
7.76%
11.81%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
386
453
469
496
1,805
2025
563
673
721
973
2,930
2026
1,036
1,430
1,632
- -
5,387

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.13
-0.64
-1.14
- -
-5.59
2025
-4.8
-4.57
-6.8
-4.57
-20.68
2026
-4.92
-9.44
-4.13
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.01
2025
- -
- -
- -
- -
1
2026
- -
- -
- -
- -
- -
Similar Companies
Biotest AG (BIESF)
Green Cross Holdings Corporation (005250.KS)
Alterity Therapeutics Limited (ATH.AX)
Avidity Biosciences Inc (RNAM)
Alligator Bioscience AB (publ) (ATORX.ST)
Poseida Therapeutics, Inc. (PSTX)
Business
Zota Health Care Limited (ZOTA.NS) manufactures, markets, and distributes a broad portfolio of pharmaceutical and healthcare products in India. The company offers finished dosage formulations including tablets, capsules, syrups, ointments, injectables, and dry syrups across therapeutic categories such as anti-infectives, gastro-intestinal, pain management, vitamins and minerals, anti-diabetics, cardiac care, dermatology, and nutraceuticals; it also provides active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and contract manufacturing services for generics and branded formulations. Zota Health Care operates primarily in the Indian pharmaceutical sector, targeting retail pharmacies, hospitals, clinics, and institutional customers nationwide, with distribution through a network of carrying and forwarding agents and super stockists. Founded in 2000 and headquartered in Surat, Gujarat, the company maintains manufacturing facilities compliant with WHO-GMP standards and focuses on domestic markets while exploring export opportunities. In recent developments, Zota Health Care reported robust financial growth in fiscal year 2025, with revenue increasing over 20% year-over-year driven by expanded production capacity and new product launches in high-demand segments like anti-infectives and chronic therapies; it also strengthened its market position through strategic investments in R&D for specialty generics and enhanced supply chain efficiencies amid industry consolidation.